Literature DB >> 28070175

A SPECIAL MEETING REVIEW EDITION: Advances in the Treatment of Hepatitis C Virus Infection From the 2016 EASL Meeting: The Annual Meeting of the European Association for the Study of the Liver • April 13-17, 2016 • Barcelona, SpainSpecial Reporting on:• Six Weeks of Sofosbuvir/Ledipasvir (SOF/LDV) Are Sufficient to Treat Acute Hepatitis C Virus Genotype 1 Monoinfection: The HepNet Acute HCV IV Study• Treatment of Hepatitis C Virus in Patients With Advanced Cirrhosis: Always Justified? Analysis of the HEPA-C Registry• High Efficacy of Sofosbuvir/Velpatasvir Plus GS-9857 in Previously Treated Patients With HCV Genotypes 1 Through 6• Prevalence and Impact of Baseline Resistance-Associated Variants (RAVs) on the Efficacy of Ledipasvir/Sofosbuvir or Simeprevir/Sofosbuvir Against GT1 HCV Infection: HCV-TARGET Interim Analysis• Sofosbuvir/Velpatasvir for 12 Weeks in Patients Coinfected With HCV and HIV-1: The ASTRAL-5 Study• 100% SVR12 With ABT-493 and ABT-530 With or Without Ribavirin in Treatment-Naive HCV Genotype 3-Infected Patients With CirrhosisPLUS Meeting Abstract SummariesWith Expert Commentary by:Steven L. Flamm, MDChief, Liver Transplantation ProgramProfessor of Medicine and SurgeryNorthwestern University Feinberg School of MedicineChicago, Illinois.

.   

Abstract

Entities:  

Year:  2016        PMID： 28070175      PMCID： PMC5210025     

Source DB:  PubMed          Journal:  Gastroenterol Hepatol (N Y)        ISSN： 1554-7914


× No keyword cloud information.
  19 in total

1.  Treatment of acute hepatitis C with interferon alfa-2b.

Authors:  E Jaeckel; M Cornberg; H Wedemeyer; T Santantonio; J Mayer; M Zankel; G Pastore; M Dietrich; C Trautwein; M P Manns
Journal:  N Engl J Med       Date:  2001-11-15       Impact factor: 91.245

2.  Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study.

Authors:  Rainer Weber; Caroline A Sabin; Nina Friis-Møller; Peter Reiss; Wafaa M El-Sadr; Ole Kirk; Francois Dabis; Matthew G Law; Christian Pradier; Stephane De Wit; Börje Akerlund; Gonzalo Calvo; Antonella d'Arminio Monforte; Martin Rickenbach; Bruno Ledergerber; Andrew N Phillips; Jens D Lundgren
Journal:  Arch Intern Med       Date:  2006 Aug 14-28

3.  Delayed versus immediate treatment for patients with acute hepatitis C: a randomised controlled non-inferiority trial.

Authors:  Katja Deterding; Norbert Grüner; Peter Buggisch; Johannes Wiegand; Peter R Galle; Ulrich Spengler; Holger Hinrichsen; Thomas Berg; Andrej Potthoff; Nisar Malek; Anika Großhennig; Armin Koch; Helmut Diepolder; Stefan Lüth; Sandra Feyerabend; Maria Christina Jung; Magdalena Rogalska-Taranta; Verena Schlaphoff; Markus Cornberg; Michael P Manns; Heiner Wedemeyer
Journal:  Lancet Infect Dis       Date:  2013-03-22       Impact factor: 25.071

4.  Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options.

Authors:  Ira M Jacobson; Stuart C Gordon; Kris V Kowdley; Eric M Yoshida; Maribel Rodriguez-Torres; Mark S Sulkowski; Mitchell L Shiffman; Eric Lawitz; Gregory Everson; Michael Bennett; Eugene Schiff; M Tarek Al-Assi; G Mani Subramanian; Di An; Ming Lin; John McNally; Diana Brainard; William T Symonds; John G McHutchison; Keyur Patel; Jordan Feld; Stephen Pianko; David R Nelson
Journal:  N Engl J Med       Date:  2013-04-23       Impact factor: 91.245

Review 5.  Review article: HCV genotype 3 – the new treatment challenge.

Authors:  J Ampuero; M Romero-Gómez; K R Reddy
Journal:  Aliment Pharmacol Ther       Date:  2014-04       Impact factor: 8.171

6.  Global distribution and prevalence of hepatitis C virus genotypes.

Authors:  Jane P Messina; Isla Humphreys; Abraham Flaxman; Anthony Brown; Graham S Cooke; Oliver G Pybus; Eleanor Barnes
Journal:  Hepatology       Date:  2014-07-28       Impact factor: 17.425

7.  Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence.

Authors:  Fred Poordad; Eugene R Schiff; John M Vierling; Charles Landis; Robert J Fontana; Rong Yang; Fiona McPhee; Eric A Hughes; Stephanie Noviello; Eugene S Swenson
Journal:  Hepatology       Date:  2016-03-07       Impact factor: 17.425

8.  Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection.

Authors:  Jordan J Feld; Ira M Jacobson; Christophe Hézode; Tarik Asselah; Peter J Ruane; Norbert Gruener; Armand Abergel; Alessandra Mangia; Ching-Lung Lai; Henry L Y Chan; Francesco Mazzotta; Christophe Moreno; Eric Yoshida; Stephen D Shafran; William J Towner; Tram T Tran; John McNally; Anu Osinusi; Evguenia Svarovskaia; Yanni Zhu; Diana M Brainard; John G McHutchison; Kosh Agarwal; Stefan Zeuzem
Journal:  N Engl J Med       Date:  2015-11-16       Impact factor: 91.245

9.  Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis.

Authors:  Michael P Curry; Jacqueline G O'Leary; Natalie Bzowej; Andrew J Muir; Kevin M Korenblat; Jonathan M Fenkel; K Rajender Reddy; Eric Lawitz; Steven L Flamm; Thomas Schiano; Lewis Teperman; Robert Fontana; Eugene Schiff; Michael Fried; Brian Doehle; Di An; John McNally; Anu Osinusi; Diana M Brainard; John G McHutchison; Robert S Brown; Michael Charlton
Journal:  N Engl J Med       Date:  2015-11-16       Impact factor: 91.245

10.  Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis.

Authors:  Graham R Foster; William L Irving; Michelle C M Cheung; Alex J Walker; Benjamin E Hudson; Suman Verma; John McLauchlan; David J Mutimer; Ashley Brown; William T H Gelson; Douglas C MacDonald; Kosh Agarwal
Journal:  J Hepatol       Date:  2016-01-30       Impact factor: 30.083
View more
  7 in total

Review 1.  Clinically Significant Drug-Drug Interactions Between Hepatitis C Virus and HIV Treatments.

Authors:  Jennifer J Kiser
Journal:  Top Antivir Med       Date:  2016 Oct/Nov

2.  A SPECIAL MEETING REVIEW EDITION: Advances in the Treatment of Hepatitis C Virus Infection From the 2016 EASL Meeting: The Annual Meeting of the European Association for the Study of the Liver • April 13-17, 2016 • Barcelona, SpainSpecial Reporting on:• Six Weeks of Sofosbuvir/Ledipasvir (SOF/LDV) Are Sufficient to Treat Acute Hepatitis C Virus Genotype 1 Monoinfection: The HepNet Acute HCV IV Study• Treatment of Hepatitis C Virus in Patients With Advanced Cirrhosis: Always Justified? Analysis of the HEPA-C Registry• High Efficacy of Sofosbuvir/Velpatasvir Plus GS-9857 in Previously Treated Patients With HCV Genotypes 1 Through 6• Prevalence and Impact of Baseline Resistance-Associated Variants (RAVs) on the Efficacy of Ledipasvir/Sofosbuvir or Simeprevir/Sofosbuvir Against GT1 HCV Infection: HCV-TARGET Interim Analysis• Sofosbuvir/Velpatasvir for 12 Weeks in Patients Coinfected With HCV and HIV-1: The ASTRAL-5 Study• 100% SVR12 With ABT-493 and ABT-530 With or Without Ribavirin in Treatment-Naive HCV Genotype 3-Infected Patients With CirrhosisPLUS Meeting Abstract SummariesWith Expert Commentary by:Steven L. Flamm, MDChief, Liver Transplantation ProgramProfessor of Medicine and SurgeryNorthwestern University Feinberg School of MedicineChicago, Illinois.

Authors: 
Journal:  Gastroenterol Hepatol (N Y)       Date:  2016-06

Review 3.  Potential Liver Transplant Recipients with Hepatitis C: Should They Be Treated Before or After Transplantation?

Authors:  Anil C Anand
Journal:  J Clin Exp Hepatol       Date:  2017-02-06

4.  Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct-acting antiviral treatment.

Authors:  Fred Poordad; Franco Felizarta; Armen Asatryan; Mark S Sulkowski; Robert W Reindollar; Charles S Landis; Stuart C Gordon; Steven L Flamm; Michael W Fried; David E Bernstein; Chih-Wei Lin; Ran Liu; Sandra S Lovell; Teresa I Ng; Jens Kort; Federico J Mensa
Journal:  Hepatology       Date:  2017-04-10       Impact factor: 17.425

5.  Efficacy of HCV treatment in Poland at the turn of the interferon era - the EpiTer study.

Authors:  Robert Flisiak; Joanna Pogorzelska; Hanna Berak; Andrzej Horban; Iwona Orłowska; Krzysztof Simon; Ewelina Tuchendler; Grzegorz Madej; Anna Piekarska; Maciej Jabłkowski; Zbigniew Deroń; Włodzimierz Mazur; Marcin Kaczmarczyk; Ewa Janczewska; Arkadiusz Pisula; Jacek Smykał; Krzysztof Nowak; Marek Matukiewicz; Waldemar Halota; Joanna Wernik; Katarzyna Sikorska; Iwona Mozer-Lisewska; Błażej Rozpłochowski; Aleksander Garlicki; Krzysztof Tomasiewicz; Joanna Krzowska-Firych; Barbara Baka-Ćwierz; Wiesław Kryczka; Dorota Zarębska-Michaluk; Iwona Olszok; Anna Boroń-Kaczmarska; Barbara Sobala-Szczygieł; Bronisława Szlauer; Bogumiła Korcz-Ondrzejek; Jerzy Sieklucki; Robert Pleśniak; Agata Ruszała; Barbara Postawa-Kłosińska; Jolanta Citko; Anna Lachowicz-Wawrzyniak; Joanna Musialik; Edyta Jezierska; Witold Dobracki; Beata Dobracka; Jan Hałubiec; Rafał Krygier; Anna Strokowska; Wojciech Chomczyk; Krystyna Witczak-Malinowska
Journal:  Clin Exp Hepatol       Date:  2016-11-28

6.  Hepatitis C Treatment and Barriers to Eradication.

Authors:  Monica A Konerman; Anna S F Lok
Journal:  Clin Transl Gastroenterol       Date:  2016-09-22       Impact factor: 4.488

Review 7.  Who to Test for Hepatitis C Virus in the Middle East and North Africa?: Pooled Analyses of 2,500 Prevalence Measures, Including 49 Million Tests.

Authors:  Hiam Chemaitelly; Sarwat Mahmud; Silva P Kouyoumjian; Zaina Al-Kanaani; Joumana G Hermez; Laith J Abu-Raddad
Journal:  Hepatol Commun       Date:  2019-01-23
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.